 anticip build dmd
pt increas ad gene therapi
program model
investor enthusiasm sarepta micro-dystrophin gene therapi program
overshadow neg outcom chmp trend vote eteplirsen
sens posit tone manag micro-dystrophin gene
therapi program ad program model believ
new partnership sarepta myonexu could support sarepta
long-term growth spent time review current competit
landscap gene therapi dmd literatur limb-girdl muscular
dystrophi lgmd increas pt
sarepta balanc sheet remain strong march sarepta
approxim cash cash equival invest compar
decemb compani record net product
revenu in-lin street consensu strong
revenu primarili reflect increas demand
believ growth sarepta revenu continu meet compani
guidanc rang increas opex
expens compar primarili due compani
on-going late-stag clinic trial preclin studi global expans
compens expens driven net increas head count
believ compani suffici cash fund oper
expens capit expenditur
tr target
increas pt pt averag fair valu
calcul use discount earn model dcf modal clinic npv model chang
made model project includ
believ ema approv eteplirsen eu base follow
chmp neg trend vote eteplirsen
 manag well cautiou view outcom potenti re-examin
regul
 neg outcom phase confirmatori trial promovi abl
use evid efficaci support potenti eu re-submiss
result remov eu revenu eteplirsen model top-lin data
confirmatori studi like present patient enrol complet studi
complet date may accord clinicaltri org
includ sarepta micro-dystrophin gene therapi program model base
compani lead posit develop gene therapi product dmd
manag perceiv confid preliminari efficaci data present june
compani day project ww revenu assign
probabl success micro-dystrophin gene therapi program out-year
assum neg outcom promovi remov
model post expect top-lin readout fda far less clear say least
regulatori approach eteplirsen posit outcom confirmatori phase trial requir
receiv final approv drug receiv condit approv acceler
approv pathway confirmatori trial sarepta eteplirsen promovi expect
announc top-lin data believ even assum neg outcom promovi
remain market follow reason
approv clinic data pressur appli dmd advocaci
group clinic data seem hold weight agenc regard eteplirsen
tecentriq atezolizumab roch rhhbi nr urotheli cancer approv fda
acceler approv pathway subsequ confirmatori phase trial fail
june howev fda taken action remov drug market
micro-dystrophin gene therapi spotlight expect posit efficaci data june
compani day
sarepta hold compani first day june compani present preliminari
efficaci data least two patient phase i/ii micro-dystrophin gene therapi studi
collabor nationwid children hospit data includ measur micro-
dystrophin express local well biomark relat dmd progress
manag use exon skip exampl exemplifi potenti strong effect dystophin
product micro-dystrophin gene therapi program natur occur exon skip
exon amen boy confer undetect dystrophin eteplirsen
measur blot despit small amount dystrophin product boy remain
ambulatori three five year longer dmd boy exon mutat regard
micro-dystrophin program manag believ normal dystrophin level measur
blot provid clinic benefit normal level dystrophin would
consid homerun sens confid manag anticip posit data
micro-dystrophin gene therapi trial posit preliminari data could provid strong tail-wind
share cement lead posit sarepta race solid bioscienc
nr buy john bori develop gene therapi dmd
exhibit competit landscap gene therapi dmd
page
new partnership potenti broaden sarepta franchis beyond dmd
sarepta announc partnership myonexu therapeut advanc multipl gene
term agreement sarepta make up-front payment million addit
development-rel mileston payment purchas exclus option acquir myonexu
pre-negoti fix price sales-rel conting payment development-rel mileston
payment met sarepta make payment million approxim two-year
evalu period sarepta option purchas myonexu time includ upon review
proof-of-concept data
lgmd genet clinic heterogen group rare muscular dystrophi diseas
character progress muscl wast affect predominantli hip shoulder muscl
lgmd categor two famili famili autosom domin
famili autosom recess accord analysi pegoraro hoffman
estim preval form lgmd rang one one
current myonexu therapeut total five program distinct form lead
program aim treat gener encourag preclin safeti
efficaci data lgmd gene therapi program util vector system vector
use micro-dystrophin program phase i/iia studi initi
sarepta expect report biopsi data earli
louis rodino-klapac ph princip investig center gene therapi nationwid
children hospit associ professor depart pediatr ohio state univers
inventor myonexu portfolio lgmd candid chief scientif offic
co-found myonexu spin-out nationwid children hospit center gene therapi
dr rodino-klapac co-inventor serv one princip investig micro-
encourag sarepta strateg move expand compani franchis beyond dmd
believ potenti acquisit myonexu could signific upsid sarepta long-term
valu well share
neg trend vote chmp eteplirsen cloud probabl approv chmp
cast neg trend vote eteplirsen part due use extern control compar
meet regulatori criteria howev chmp conclud eteplirsen ineffect
sarepta plan file re-examin request scientif advisori group sag provid
guidanc insight valid extern control even though addit data would
allow present final vote eteplirsen held end may potenti
re-examin expect complet project approv eteplirsen eu
near-term remov revenu eteplirsen eu model
golodirsen aa submiss could deliv strong momentum share march sarepta
announc compani plan complet roll nda submiss acceler approv
aa golodirsen compani investig exon-skip drug duchenn
muscular dystrophi dmd amen exon sarepta made decis base result
page
studi feedback compani februari type meet fda
regard regulatori path golodirsen sarepta expect complet nda submiss
believ accept submiss file could boost share
page
 model mm except per share result
ww casimersen golodirsen sale revenu
revenu licens fee grant research contract
sale
net revenu
research develop
sell gener administr
amort in-licens right
exondi litig licens charg
requir disclosur last tab workbook
close price
sale intang asset
interest incom net
loss chang warrant valuat
total incom loss
incom loss incom tax expens
net incom loss per share basic dilut
page
eteplirsen duchenn muscular dystrophi dmd
eteplirsen dmd
annual number birth mm
incid dmd male infant
annual incid dmd
averag life span dmd patient
 preval dmd
averag age diagnosi
number diagnos dmd patient
dmd patient treatabl exon skip
number dmd patient elig eteplirsen treatment
market penetr eteplirsen
number dmd patient receiv eteplirsen treatment
close price
requir disclosur last tab workbook
